Since leronlimab is a humanized monoclonal IgG4 antibody it falls into the immunoglobulin G (IgG) family. All classes of IgG have a similar molecular mass but have differing binding and triggering characteristics.

Good discussion of IgG subclasses and Allotypes can be found here.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202688/

They are working on it and have been very successful in determining the most efficient administration techniques as seen in this study.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851908/

Quote:

---

In summary, our data demonstrate that a significant fraction of systemically administered IVIg reaches the cerebral microvessels and enters the brain through a saturable transport across the BBB. To our knowledge, this study is the first to provide quantitative measurement of IVIg brain entry and suggests that IVIg may interact with therapeutic targets within the CNS, in the absence of BBB leakage.

---

A deep dive on mAb pathways across the BBB can be read here:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023012/

Long story short....Yes, the precedent has been proven successfully, now to see if the scientific medical community can perform a study specifically on leronlimab. Need a partner like MD Anderson, Thomas Jefferson University, or other respected research institution to take that on.